Remibrutinib: Regulatory submission for chronic spontaneous urticaria in 2025 (Novartis) - Jul 17, 2024 - Q2 2024 Results: Regulatory submission for multiple sclerosis in 2027 or later
Filing • Chronic Spontaneous Urticaria • Immunology • Multiple Sclerosis
|